Generics BulletinExecutive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.
Generics BulletinAt the midway point of 2023, dealmaking for big pharma had roared back to life following relative austerity in the previous two years, as credit became harder to come by, interest rates spiked, and le
In VivoAt the midway point of 2023, dealmaking for big pharma had roared back to life following relative austerity in the previous two years, as credit became harder to come by, interest rates spiked, and le
In VivoChange is a constant theme for our annual Generics Bulletin Top 50 ranking of the world’s leading generics and biosimilars companies, and this year’s rundown of off-patent industry titans is no diff